Bridgebio Stock Analysis


USD 9.24  0.16  1.76%   

The latest indifference towards the small price fluctuations of Bridgebio Pharma could raise concerns from institutional investors as the firm is trading at a share price of 9.24 on very low momentum in volume. The company executives did not add any value to Bridgebio Pharma investors in May. However, most investors can still diversify their portfolios with Bridgebio Pharma to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.2. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Bridgebio Pharma partners.
Continue to Trending Equities.
The Bridgebio Pharma stock analysis report makes it easy to digest most publicly released information about Bridgebio Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bridgebio Stock analysis module also helps to analyze the Bridgebio Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Bridgebio Stock Analysis Notes

About 95.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Bridgebio Pharma recorded a loss per share of 3.88. The entity had not issued any dividends in recent years. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people. For more info on Bridgebio Pharma please contact the company at 650 391 9740 or go to

Bridgebio Pharma Quarterly Cost of Revenue

1.35 Million


Bridgebio Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bridgebio Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bridgebio Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bridgebio Pharma has very high historical volatility over the last 90 days
Bridgebio Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 69.72 M. Net Loss for the year was (562.54 M) with profit before overhead, payroll, taxes, and interest of 66.6 M.
Bridgebio Pharma currently holds about 836.66 M in cash with (497.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67.
Bridgebio Pharma has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Ellis Andrea of 104921 shares of Bridgebio Pharma subject to Rule 16b-3

Bridgebio Pharma Upcoming and Recent Events

Earnings reports are used by Bridgebio Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bridgebio Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Bridgebio Largest EPS Surprises

Earnings surprises can significantly impact Bridgebio Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Bridgebio Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bridgebio Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bridgebio Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bridgebio Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
18th of May 2022
Financial Statements and Exhibits. Other Events. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
13th of May 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
10th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
24th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of February 2022
Unclassified Corporate Event
9th of February 2022
Unclassified Corporate Event
3rd of February 2022
Unclassified Corporate Event
27th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure

Bridgebio Pharma Thematic Classifications

In addition to having Bridgebio Pharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Bridgebio Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Bridgebio Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bridgebio Pharma backward and forwards among themselves. Bridgebio Pharma's institutional investor refers to the entity that pools money to purchase Bridgebio Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Kohlberg Kravis Roberts Co LpCommon Shares31.1 M315.3 M
Viking Global Investors LpCommon Shares26.6 M270.2 M
Vanguard Group IncCommon Shares9.4 M95.7 M
State Street CorpCommon Shares9.2 M93.4 M
Blackrock IncCommon Shares9.1 M92.8 M
Aisling Capital Management LpCommon Shares6.1 M61.6 M
Aristeia Capital LlcDebt100.2 M60.1 M
Hhlr Advisors LtdCommon Shares5.4 M54.4 M
Note, although Bridgebio Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bridgebio Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.17 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bridgebio Pharma's market, we take the total number of its shares issued and multiply it by Bridgebio Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Bridgebio Profitablity

Bridgebio Pharma's profitability indicators refer to fundamental financial ratios that showcase Bridgebio Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Bridgebio Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bridgebio Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bridgebio Pharma's profitability requires more research than a typical breakdown of Bridgebio Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.57) (0.61) 
Return on Average Equity 0.91  0.98 
Return on Invested Capital(0.26) (0.28) 
Return on Sales(7.40) (7.98) 

Management Efficiency

The entity has return on total asset (ROA) of (41.75) % which means that it has lost $41.75 on every $100 spent on asset. This is way below average. Bridgebio Pharma management efficiency ratios could be used to measure how well bridgebio pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is expected to rise to 0.98 this year, although the value of Return on Average Assets will most likely fall to (0.61) . Bridgebio Pharma Assets Non Current are quite stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 133.72 Million. Tangible Assets Book Value per Share is expected to rise to 6.93 this year, although the value of Total Assets will most likely fall to about 870.1 M.
Last ReportedProjected for 2022
Book Value per Share(6.03) (6.19) 
Enterprise Value over EBIT(7.00) (7.55) 
Enterprise Value over EBITDA(7.28) (7.86) 
Price to Book Value(2.82) (2.89) 
Tangible Assets Book Value per Share 6.71  6.93 
Enterprise Value3.7 B4.2 B
Tangible Asset Value967.9 M841.3 M

Technical Drivers

As of the 26th of June, Bridgebio Pharma shows the mean deviation of 5.5, and Risk Adjusted Performance of 0.0029. Bridgebio Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Bridgebio Pharma, which can be compared to its rivals. Please confirm Bridgebio Pharma variance, as well as the relationship between the maximum drawdown and semi variance to decide if Bridgebio Pharma is priced correctly, providing market reflects its regular price of 9.24 per share. Given that Bridgebio Pharma has jensen alpha of 0.3381, we suggest you to validate Bridgebio Pharma's prevailing market performance to make sure the company can sustain itself at a future point.

Bridgebio Pharma Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Mid-point over period is an average of Bridgebio Pharma highest and lowest values attained during the given period.

Bridgebio Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bridgebio Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bridgebio Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bridgebio Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ellis Andrea 2 days ago via Macroaxis 
Acquisition by Ellis Andrea of 104921 shares of Bridgebio Pharma subject to Rule 16b-3
Kumar Neil over three weeks ago via Macroaxis 
Exercise or conversion by Kumar Neil of 68705 shares of Bridgebio Pharma subject to Rule 16b-3
Stephenson Brian C over a month ago via Macroaxis 
Exercise or conversion by Stephenson Brian C of 24192 shares of Bridgebio Pharma subject to Rule 16b-3
Ellis Andrea over three months ago via Macroaxis 
Purchase by Ellis Andrea of 12000 shares of Bridgebio Pharma
Dachille Douglas A over three months ago via Macroaxis 
Purchase by Dachille Douglas A of 10000 shares of Bridgebio Pharma
Scheller Richard H over three months ago via Macroaxis 
Acquisition by Scheller Richard H of 25566 shares of Bridgebio Pharma subject to Rule 16b-3
Stephenson Brian C over three months ago via Macroaxis 
Exercise or conversion by Stephenson Brian C of 778 shares of Bridgebio Pharma subject to Rule 16b-3
Dachille Douglas A over three months ago via Macroaxis 
Purchase by Dachille Douglas A of 5000 shares of Bridgebio Pharma
Valantine Hannah over three months ago via Macroaxis 
Purchase by Valantine Hannah of 1764 shares of Bridgebio Pharma
Daniels Ronald J over three months ago via Macroaxis 
Purchase by Daniels Ronald J of 10402 shares of Bridgebio Pharma
Scheller Richard H over six months ago via Macroaxis 
Acquisition by Scheller Richard H of 16685 shares of Bridgebio Pharma subject to Rule 16b-3
Valantine Hannah over six months ago via Macroaxis 
Acquisition by Valantine Hannah of 50968 shares of Bridgebio Pharma subject to Rule 16b-3

Bridgebio Pharma Technical and Predictive Indicators

Bridgebio Pharma Forecast Models

Bridgebio Pharma time-series forecasting models is one of many Bridgebio Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bridgebio Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Bridgebio Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bridgebio Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bridgebio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Bridgebio Pharma. By using and applying Bridgebio Stock analysis, traders can create a robust methodology for identifying Bridgebio entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(7.23) (7.81) 
Gross Margin 0.95  1.06 
Profit Margin(8.07) (8.70) 
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people.

Current Bridgebio Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bridgebio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bridgebio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Bridgebio Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bridgebio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bridgebio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bridgebio Pharma, talking to its executives and customers, or listening to Bridgebio conference calls.
Bridgebio Analyst Advice Details

Bridgebio Stock Analysis Indicators

Bridgebio Pharma stock analysis indicators help investors evaluate how Bridgebio Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bridgebio Pharma shares will generate the highest return on investment. By understating and applying Bridgebio Pharma stock analysis, traders can identify Bridgebio Pharma position entry and exit signals to maximize returns.
Quick Ratio6.34
Fifty Two Week Low4.98
Revenue Growth10,462.30%
Shares Short Prior Month19.3M
Average Daily Volume Last 10 Day2.27M
Average Daily Volume In Three Month2.11M
Shares Percent Shares Out13.14%
Gross Margins95.53%
Short Percent Of Float23.74%
Forward Price Earnings-2.55
Float Shares78.92M
Fifty Two Week High65.33
Enterprise Value To Ebitda-3.66
Fifty Day Average8.02
Two Hundred Day Average23.95
Enterprise Value To Revenue29.83
Continue to Trending Equities. Note that the Bridgebio Pharma information on this page should be used as a complementary analysis to other Bridgebio Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Bridgebio Stock analysis

When running Bridgebio Pharma price analysis, check to measure Bridgebio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridgebio Pharma is operating at the current time. Most of Bridgebio Pharma's value examination focuses on studying past and present price action to predict the probability of Bridgebio Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bridgebio Pharma's price. Additionally, you may evaluate how the addition of Bridgebio Pharma to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Global Correlations
Find global opportunities by holding instruments from different markets
CEO Directory
Screen CEOs from public companies around the world
Is Bridgebio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bridgebio Pharma. If investors know Bridgebio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bridgebio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.4 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Bridgebio Pharma is measured differently than its book value, which is the value of Bridgebio that is recorded on the company's balance sheet. Investors also form their own opinion of Bridgebio Pharma's value that differs from its market value or its book value, called intrinsic value, which is Bridgebio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bridgebio Pharma's market value can be influenced by many factors that don't directly affect Bridgebio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bridgebio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Bridgebio Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bridgebio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.